Acellular matrix hydrogel modified bone scaffold as well as preparation method and application thereof
By introducing a decellular matrix hydrogel on the surface of the bone scaffold, stem cell development regression is induced, and the problem that existing bone replacement materials cannot achieve bone regeneration is solved, the bone regeneration treatment effect is improved, and the inflammatory response is reduced.
Patent Information
- Application Number
- CN202411084386.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-22
AI Technical Summary
The existing bone alternative materials cannot effectively induce bone regeneration, ignore the importance of key biological signals during growth and development, and cannot achieve 'bone development regression'.
The bone scaffold is modified by acellular matrix hydrogel, and the acellular matrix hydrogel is introduced into the embryonic or growth-development phase on the surface of the bone scaffold to induce stem cell development regression, reconstruct the bone growth and development microenvironment, and promote bone regeneration.
It improves the effect of bone regeneration treatment, enhances the quality of osteogenesis, achieves complete regeneration of bone defects, reduces inflammation and foreign body reactions, and has good biological activity and low immunogenicity.
Smart Images

Figure CN118987353A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medical materials, and in particular to a decellularized matrix hydrogel-modified bone scaffold and a preparation method and application thereof. Background Art
[0002] Diseases such as tumors, trauma, congenital developmental defects, osteomyelitis, periodontitis and tooth loss are highly prevalent and are usually complicated by bone defects. Maxillofacial bone defects can affect the retention, stability and functionality of dentures, and endanger the reconstruction of the patient's appearance, chewing, language and other oral and maxillofacial complex functions; long bone defects can affect the motor function and load-bearing capacity of the limbs. Bone defects greatly interfere with patients' daily social activities, quality of life and mental health. At present, bone replacement materials are commonly used in clinical practice to treat bone defects, among which bone scaffold materials are easier to achieve bone regeneration due to their good osteogenic space support and stability.
[0003] Today's society has an increasing demand for bone regeneration treatment. On the one hand, with the aggravation of population aging, the incidence and difficulty of bone defects have increased, and the demand for effective treatment methods has also increased. On the other hand, with the development of disciplines such as oral implantology and prosthodontics and the improvement of living standards, people have put forward higher requirements for the quality and quantity of bone defect repair. Bone regeneration can form perfect tissue organs from scratch. It is a complex multi-stage process involving continuous cellular events, the synergy of multiple systems, including close cooperation between cells and between cells and their microenvironment, and the spatiotemporal sequential evolution during the differentiation of pluripotent lineages. During the development of the skull, craniomaxillofacial neural crest cells need to undergo migration, coagulation, differentiation, matrix secretion and remodeling mineralization under the mediation of the extracellular matrix, providing an ideal evolutionary framework for complete bone regeneration. The development of bone scaffolds that can induce true bone tissue regeneration has become the development goal of bone replacement materials in the next stage.
[0004] The concept of "bone development regression" is to simulate or reproduce the bone growth and development process based on the principle of embryonic and juvenile bone growth and development to promote organ regeneration. It is a new direction of regenerative medicine with great potential. In the process of tissue regeneration in adults, by constructing a complex growth and development signal network to simulate the special microenvironment of tissue growth and development, key signals such as mesenchymal coagulation and epithelial-mesenchymal interaction are given to adult stem cells in imitation of growth and development, inducing bone damaged tissue to follow the pattern of the development period (bone development regression) and achieve regeneration of complete tissue structure.
[0005] The modified bone scaffold that "promotes bone development regression" needs to carry rich bone growth and development signals, and induce the expression of SLUG, RUNX 2, SOC9, CXCL12, SOX9, TWIST1 genes by activating specific growth and development signal pathways such as Wnt, FGF, BMP and TGF-β, thereby initiating bone development programmed events such as epithelial-mesenchymal transition, the generation and migration of neural crest cells, and the maturation of osteoblasts, and promoting the expression of important genes for cartilage formation, reconstructing a special bone growth and development microenvironment, and achieving the reproduction of key developmental programmed events during growth and development.
[0006] Existing bone replacement materials often only focus on the physical support of the material, ignoring the importance of key biological signals during the growth and development period, and thus cannot achieve bone regeneration of "bone development regression". Therefore, research on bone replacement materials with the function of promoting bone development regression has become the research frontier in the field of bone regeneration. Summary of the invention
[0007] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a decellularized matrix hydrogel modified bone scaffold, which is prepared by introducing decellularized matrix hydrogel on the surface of the bone scaffold, and can induce stem cell development regression to promote bone regeneration and match the needs of different bone defect areas.
[0008] To achieve the above object, the technical solution adopted by the present invention is:
[0009] In the first aspect, the present invention provides a decellularized matrix hydrogel modified bone scaffold, wherein the decellularized matrix hydrogel modified bone scaffold is formed by in situ cross-linking of a decellularized matrix hydrogel and a bone scaffold; the decellularized matrix hydrogel is prepared from tissues and organs in the embryonic period or the growth and development period; the bone scaffold includes at least one of autologous bone, xenogeneic bone and synthetic material.
[0010] Bone regeneration is a complex multi-stage process involving continuous cellular events, the synergy of multiple systems, including close cooperation between cells, between cells and their microenvironment, and the spatiotemporal sequential evolution during the differentiation of pluripotent lineages. In order to enhance the effect of bone regeneration, improve the quality of osteogenesis, and achieve complete bone regeneration based on previous studies, skull development can be used as a framework for bone regeneration to comprehensively and precisely regulate the above factors, promote adult bone regeneration in a similar pattern to bone development, and achieve bone development regression. The present invention prepares a decellularized matrix hydrogel modified bone scaffold, wherein the bone scaffold can provide mechanical support for bone defects and provide a scaffold for bone growth, promote bone cell attachment and proliferation, and induce new bone formation. The extracellular matrix is a cellular matrix component secreted by cells and present around cells. It is an insurmountable medium in the process of cell-to-cell and cell-to-microenvironment interaction; it not only provides physical support for cells and an interaction medium with the outside world, but also participates in a variety of cell activities such as signal transduction within cells, between cells, and between cells and microenvironment, and comprehensively shapes the microenvironment of bone development in the embryonic period. The present invention introduces acellular matrix hydrogel on the surface of bone scaffold to prepare embryonic or growth and development period acellular matrix hydrogel modified bone scaffold with the function of inducing stem cell development regression. The specific extracellular matrix of the animal body is used to reshape stem cells and biological microenvironment, induce stem cell development regression, and then achieve bone redevelopment through the strong osteogenic ability of stem cells after development regression, and treat bone defect regeneration in adult individuals.
[0011] Preferably, the present invention performs in situ cross-linking by physical freeze-drying.
[0012] Preferably, the tissues and organs are of animal origin.
[0013] Preferably, the tissues and organs include bone tissue and soft tissue.
[0014] More preferably, the bone tissue comprises skull bone tissue.
[0015] Preferably, the autologous bone and the xenogeneic bone are both bone tissues of animal origin; and the synthetic material includes at least one of bioglass, calcium phosphate, polylactic acid, and polyglycolic acid.
[0016] Preferably, the autologous bone is bone tissue obtained from the same individual, including but not limited to cortical bone blocks, cortical cancellous bone blocks, cortical bone particles, cancellous bone particles and bone chips from the mandibular symphysis, mandibular ramus, external oblique crest, iliac crest, proximal ulna or distal radius; the allogeneic bone includes allogeneic bone; the allogeneic bone is various forms of bone tissue obtained from compatible living donors or cadaveric bone sources; the source of the xenogeneic bone includes but is not limited to pig bone, cattle bone and sheep bone.
[0017] Preferably, the bioglass includes but is not limited to silica bioglass and borate bioglass.
[0018] Preferably, the calcium phosphate includes hydroxyapatite, tricalcium phosphate, or dicalcium phosphate.
[0019] Preferably, the animal source includes but is not limited to rats, mice, pigs, sheep, cattle, and horses.
[0020] More preferably, the bone scaffold is a porcine bone-derived biological calcium apatite scaffold.
[0021] In a second aspect, the present invention provides a method for preparing the above-mentioned decellularized matrix hydrogel-modified bone scaffold, comprising the following steps:
[0022] (1) Taking bone tissue from animal sources, removing excess tissue, defatting, washing, drying, and calcining to obtain a bone scaffold; or taking synthetic materials and subjecting them to chemical treatment to obtain a bone scaffold;
[0023] (2) taking tissues and organs from the embryonic stage or the growth and development stage, subjecting them to decellularization and matrix digestion to obtain a decellularized matrix hydrogel stock solution;
[0024] (3) The decellularized matrix hydrogel stock solution obtained in step (2) is mixed with the bone scaffold obtained in step (1), and the decellularized matrix hydrogel-modified bone scaffold is obtained by in situ cross-linking, freezing, and drying.
[0025] Preferably, in step (1), the degreasing method is to first soak in a hydrogen peroxide solution and then soak in anhydrous ethanol.
[0026] Preferably, the concentration of the hydrogen peroxide solution is 10% to 30%, and the soaking time is 24 hours.
[0027] Preferably, the anhydrous ethanol soaking time is 24 hours.
[0028] Preferably, the slicing is performed before calcining.
[0029] Preferably, the cutting process is: cutting the bone tissue into cylinders with a thickness of 1 mm and a cross-sectional diameter of 5 mm.
[0030] Preferably, the calcination conditions are: temperature 400-1000° C., time 2-6 h.
[0031] Preferably, in step (2), the tissue and organ are mouse embryos on the 15th day of development.
[0032] Preferably, in step (2), the decellularization treatment method includes at least one of a physical method, a chemical method, and an enzymatic method.
[0033] Preferably, the physical method includes but is not limited to repeated freezing and thawing, ultrasonic treatment, and high hydrostatic pressure; the chemical method includes but is not limited to treatment with SDS and Triton-100, acetone, methanol, acetic acid, sodium hydroxide, and ethanol; the enzymatic method includes but is not limited to treatment with trypsin, pepsin, endonuclease, and exonuclease.
[0034] Preferably, the decellularization method is: first soaking in a PBS solution containing 1% Triton-100 (w / w) for 24 hours, and then soaking in a PBS solution containing 1% SDS (w / w) for 48 hours.
[0035] Preferably, in step (2), the substrate is digested by enzymes.
[0036] Preferably, the enzyme comprises at least one of pepsin, trypsin, epithelial dissociation enzyme, and collagenase.
[0037] Preferably, the digestion method is: soaking in a 0.01 M hydrochloric acid solution containing 1 mg / mL pepsin (3000-3500 NFU / g) for 2 weeks.
[0038] Preferably, in step (2), after the substrate is digested, an alkali solution is added to adjust the pH to 7.0 to terminate the digestion.
[0039] Preferably, the alkali solution comprises NaOH solution, Na 2 CO 3 Solution, ammonia.
[0040] Preferably, in step (3), the mixing method is to drop the decellularized matrix hydrogel stock solution onto the bone scaffold.
[0041] Preferably, the volume of the decellularized matrix hydrogel stock solution added is selected according to the size of the material, so that the stock solution can cover the material.
[0042] Preferably, in step (3), the in situ cross-linking method includes but is not limited to:
[0043] (1) Chemical crosslinking is carried out by introducing a crosslinking agent or a crosslinking compound into the hydrogel; commonly used crosslinking agents include carboxymethyl cellulose (CMC), epoxy compounds, polyethylene glycol (PEG), and thiol compounds;
[0044] (2) thermal cross-linking using temperature changes to initiate the cross-linking reaction of hydrogels, using high or low temperature to treat hydrogel samples;
[0045] (3) introducing a photosensitizer or photoinitiator into the hydrogel and initiating a photocrosslinking reaction in the hydrogel by irradiating light of a specific wavelength;
[0046] (4) Biological cross-linking method that uses biological molecules (such as enzymes or cells) to achieve hydrogel cross-linking.
[0047] In a third aspect, the present invention provides the use of the above-mentioned decellularized matrix hydrogel-modified bone scaffold in the preparation of bone repair or bone regeneration materials.
[0048] Preferably, the acellular matrix hydrogel modified bone scaffold promotes bone repair or bone regeneration by inducing the microenvironment of bone development and stem cell development regression.
[0049] The beneficial effects of the present invention are:
[0050] The raw materials for preparing the decellular matrix hydrogel modified bone scaffold of the present invention are simple and easy to obtain. The bone scaffold has good mechanical strength to support the decellular matrix and has good bone conduction performance. The three-dimensional structural characteristics thereof are conducive to the migration, adhesion and growth of cells, thereby providing physical and chemical structures and biological signals for tissue repair and regeneration. The present invention drips the decellular matrix hydrogel stock solution on the surface of the existing bone scaffold, and obtains the decellular matrix hydrogel modified bone scaffold by in situ cross-linking by methods such as physical freeze drying. The preparation technology is simple, the cost is low, and it is suitable for mass production. In addition, the decellular matrix hydrogel loaded on the surface of the bone scaffold can realize the loading of liposomes or other nano drug carriers, and realize the precise release and treatment of drugs at the bone defect site. The decellular matrix hydrogel modified bone scaffold of the present invention induces the regression of stem cell development by shaping the bone development microenvironment in the bone defect of an adult individual, promotes bone regeneration and osteogenesis quality, and improves the bone defect regeneration treatment effect of the bone scaffold.
[0051] The decellularized matrix hydrogel of the present invention is of animal origin, has good biocompatibility, retains the main components of the extracellular matrix such as collagen, non-collagen, proteoglycan, growth factors and matrix vesicles, is similar to the natural extracellular matrix, and can significantly reduce tissue damage and healing disorders caused by inflammation and foreign body reaction.
[0052] The acellular matrix hydrogel modified bone scaffold prepared by the present invention retains the excellent performance and three-dimensional structure of the original bone scaffold. After being implanted into the body, it can match the needs of different bone defect areas. While inducing stem cell development regression, it also has good biological activity, no cytotoxicity and low immunogenicity, is easily degraded and absorbed by the body, and has good application prospects.
[0053] The present invention develops a new modified bone scaffold that "promotes bone development regression" based on the concept of "bone development regression", which is of great significance to the field of bone tissue regeneration. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1This is the stereomicroscope observation result of the decellularized matrix hydrogel modified bone scaffold prepared in Example 1.
[0055] Figure 2 This is the scanning electron microscope (SEM) observation result of the decellularized matrix hydrogel modified bone scaffold prepared in Example 1.
[0056] Figure 3 This is the Fourier transform infrared spectroscopy (FTIR) test result of the decellularized matrix hydrogel modified bone scaffold prepared in Example 1.
[0057] Figure 4 This is the result of immunohistochemical staining (IHC) of the animal experiment on the decellularized matrix hydrogel modified bone scaffold prepared in Example 1 one week after surgery.
[0058] Figure 5 This is the HE staining result of the animal experiment of the decellularized matrix hydrogel modified bone scaffold prepared in Example 1 4 weeks after surgery.
[0059] Figure 6 This is the MASSON staining result of the animal experiment on the decellularized matrix hydrogel modified bone scaffold prepared in Example 1 4 weeks after surgery. DETAILED DESCRIPTION
[0060] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0061] Unless otherwise specified, the components, raw materials or instruments used in the embodiments and comparative examples of the present invention are all commercially available raw materials or instruments, and the components and raw materials used in each parallel experiment are all of the same kind.
[0062] Example 1: Preparation of decellularized matrix hydrogel-modified bone scaffold
[0063] 1. Preparation of bone scaffold: Take cancellous bone from the epiphysis of pig femur, remove the surface soft tissue and cartilage; first soak in hydrogen peroxide solution for 24 hours, then soak in anhydrous ethanol for 24 hours for degreasing, wash with ultrapure water, and dry; cut the dried bone tissue into cylindrical blocks (height 1 mm, diameter 5 mm), calcine, wash with ultrapure water, and dry to obtain a bone scaffold;
[0064] 2. Tissue decellularization: Take the skull tissue or soft tissue of unborn embryonic mice (about 15 days before birth), defat it, and use Triton-100 and SDS to remove the cell nuclei in the embryonic tissue;
[0065] 3. Digestion of matrix in tissue: freeze-dry the above tissue and grind it into powder; add 100 mg pepsin (3000-3500 NFU / g) per gram of freeze-dried powder and mix it in 100 mL of 0.01 M HCl, and keep constant stirring at room temperature (25°C) for 48 hours to digest the organic matter in the tissue;
[0066] 4. Stop digestion: adjust the pH to 7.0 with 0.1 mol / L NaOH to obtain the decellularized matrix hydrogel stock solution;
[0067] 5. In situ cross-linking: drip the above-mentioned decellularized matrix hydrogel stock solution onto the bone scaffold, freeze-dry and perform in situ cross-linking to obtain the decellularized matrix hydrogel modified bone scaffold.
[0068] Example 2: Appearance and micromorphology characterization of decellularized matrix hydrogel-modified bone scaffolds
[0069] Test samples: decellularized matrix hydrogel modified bone scaffold (dECM-BHA) prepared in Example 1; biological bone calcium apatite scaffold (BHA, control group: bone scaffold without adding decellularized hydrogel stock solution).
[0070] 1. Observe the macroscopic surface morphology of the sample using a stereo microscope: Take a small amount of the test sample and dry it in an oven at 37°C for 24 hours. Place the sample on the observation table and observe it using a stereo microscope (Leica, Germany).
[0071] 2. Observation using a scanning electron microscope (SEM): Take a small amount of test sample and vacuum freeze-dry it for 12 hours. Place the sample on an aluminum sample table and firmly adhere it with conductive glue, spray gold for 120 seconds, and observe the sample using a field emission SEM (EOL, Japan) at a test voltage of 0.2-0.5 kV, using the integral superposition mode for testing.
[0072] 3. Fourier transform infrared spectroscopy (FTIR) test: Weigh a small amount of sample and mix it with dry potassium bromide at a ratio of 1:200. Use a tablet press to press it into a sheet with a thickness of about 1 mm, and set up three replicates for each. Use a Fourier transform infrared spectrometer-infrared microscope (Ettlingen, Germany) for testing, with a scanning range of 4000-400cm -1 .
[0073] The results of stereomicroscope observation showed that the porous structure of the blank bio-bone calcium apatite (BHA) scaffold was visible under the microscope ( Figure 1 ), the decellularized matrix hydrogel-modified bone scaffold coating has appropriate wrapping integrity and can maintain the macroscopic three-dimensional structure of the original scaffold.
[0074] Scanning electron microscopy (SEM) observations showed that the thickness of the decellularized matrix hydrogel-modified bone scaffold coating was appropriate ( Figure 2 ).
[0075] The Fourier transform infrared spectroscopy (FTIR) test results showed that the modified bone scaffold (dECM-BHA) obtained by coating biological bone calcium apatite (BHA) with decellularized matrix (dECM) exhibited an organic peak at 887 cm -1 The COC peak appears around 1187cm -1 The characteristic peaks of sulfated glycosaminoglycans appear around 1280-1560cm -1 The characteristic peak of amide bond appears around 1790cm -1 and 2181cm -1 The characteristic peaks of C=O and C≡C appear on the left and right, respectively, at 3000cm -1 NH and CH bonds appear around 560 cm -1 and 1030cm -1 The typical characteristic peaks of OP bonds and OPO bonds are shown at , and the results show that the modified bone scaffold is successfully prepared by the present invention, and the decellularized matrix hydrogel is successfully coated on the surface of the BHA bone scaffold.
[0076] Example 3: Effect of decellularized matrix hydrogel-modified bone scaffold on stem cell development regression
[0077] Test materials: decellularized matrix hydrogel modified bone scaffold (dECM-BHA) prepared in Example 1; biological bone calcium apatite scaffold (BHA, control group: bone scaffold without adding embryonic decellularized hydrogel stock solution).
[0078] Male rats aged 6-8 weeks were selected and randomly divided into groups. Atropine sulfate solution was injected intraperitoneally to protect the rats' respiratory tract. General anesthesia was performed by intramuscular injection of Shutai 50 in rats, with an injection volume of 0.15 mL per 100 g body weight.
[0079] The rats were dehaired and skinned on the top of the skull. After the rats were fixed, the skin of the rat tail and skull area was disinfected. The tail tip of the rat was cut to let blood flow out. The test material with the volume of the skull defect was mixed with the rat tail vein blood in a 1 mL syringe and left to stand until the blood was completely coagulated. 4% articaine was used for local infiltration anesthesia in the skull area. A 2 cm long incision was made from the intersection of the midline of the rat ear and the line connecting the upper edges of the two eyes along a straight line to the neck, directly reaching the bone surface, and the skin, subcutaneous tissue and mucoperiosteal flap were separated. Under 4 ° C saline flushing and cooling, two critical bone defects were made in the rat skull with a 5.0 mm diameter annular bone drill and a slow handpiece. The decellularized matrix hydrogel modified bone scaffold (dECM-BHA) and biological bone calcium apatite (BHA) scaffold prepared in Example 1 were implanted in the defect and the incision was closed. Sodium cyanobacterium (50,000 units / mouse) and analgesic (0.1 mL) were injected intramuscularly after surgery to prevent wound infection and relieve pain. After the rats recovered from anesthesia, they were returned to the animal room for routine feeding and were killed after 1 week and 4 weeks, respectively. The skull defect containing the material was cut out. The sample was fixed in 4% paraformaldehyde overnight and transferred to 75% ethanol solution for storage the next day. The skull tissue was decalcified in 4% ethylenediaminetetraacetic acid (EDTA) decalcification solution for 4 weeks, dehydrated and embedded in paraffin. The above soft and hard tissue samples were cut into 4μm thin slices using a microtome. After histopathological staining, a slice scanner was used to observe the pathological sections.
[0080] At 2 weeks after surgery, sections were subjected to immunohistochemical staining (IHC) to mark mesenchymal stem cells, immature osteoblast-related stem cells, and immature chondrogenic-related stem cells in the skull tissue.
[0081] Immunohistochemical staining steps: First, select the target slices for routine dewaxing and rehydration; permeabilize with 0.1% TritonX-100, 3% H 2 O 2 Incubate; immerse in antigen retrieval solution for heat repair recovery step. The sections were cooled to room temperature and blocked with 3% bovine serum albumin; then incubated with primary antibodies SLUG (dilution ratio 1:50), CD10 (dilution ratio 1:50), FN1 (dilution ratio 1:2000), COL1 (dilution ratio 1:50) at 4°C overnight. After incubation, the sections were washed in 0.1% TritonX-100 and PBS and incubated with goat anti-mouse / rabbit secondary antibodies at room temperature for 1 hour. Antibody complexes were observed after dripping with diaminobenzidine solution; stained with hematoxylin for 3 minutes and dehydrated conventionally. The slide holder was soaked in a transparent agent twice, 10 minutes each time; finally, neutral resin was added and coverslips were added. After drying overnight, the sections were scanned and observed in a slide scanner.
[0082] The results of immunohistochemical staining showed that compared with the biological calcium apatite scaffold group, the acellular matrix hydrogel modified bone scaffold group prepared by the present invention had a higher expression of CD10 + The number of mesenchymal stem cells in SLUG + The number of osteogenic and chondrogenic stem cells increased significantly ( Figure 4 ). This suggests that the bone formation ability of the acellular matrix hydrogel modified bone scaffold prepared by the present invention in the skull defect area is significantly improved.
[0083] The specific FN1 and COL1 morphologies were used as markers of mesenchymal stem cell aggregation. The results showed that compared with the biological calcium apatite scaffold group, the acellular matrix hydrogel modified bone scaffold group prepared by the present invention showed a certain degree of mesenchymal cell aggregation represented by FN1 and COL1, indicating that the introduction of acellular matrix hydrogel can not only significantly enhance the vitality of stem cells, but also promote their aggregation and differentiation.
[0084] Example 4: Decellularized matrix hydrogel modified bone scaffold promotes bone regeneration
[0085] Test sample: same as Example 3.
[0086] The experimental materials are shown in Example 3.
[0087] Hematoxylin and eosin staining (H&E staining): Select the maximum cross-sectional area of the target area in the tissue organ, the slice thickness is 4μm, and the slices are cut continuously as the target slices. The tissue slices are stained with hematoxylin-eosin (H&E). The target slices are placed in a slide holder and immersed in a non-toxic transparent dewaxing solution for dewaxing, 15 minutes each time, repeated twice; immersed in 100%, 75%, 30% ethanol solution, distilled water and PBS solution for rehydration, 3 minutes each time; stained with hematoxylin for 3 minutes, rinsed under running water for 3 minutes; immersed in hematoxylin differentiation solution and hematoxylin blueing solution in turn, the time is 2s and 10s respectively. Dehydrated with 70%, 90% and 100% ethanol solutions in turn, 3 minutes each time. Soak in eosin staining solution for 1 minute, and quickly soak in anhydrous ethanol 3 times. Soak the slide holder in the transparent agent twice, each time for 10 minutes; add neutral resin and cover with a cover glass; after drying overnight, scan the slide with a slide scanner for scanning and observation; the results are as follows Figure 5 shown.
[0088] Masson staining: Select the target slices, dewax and rehydrate as usual. Mix iron hematoxylin A solution and B solution in equal proportions to prepare the working solution, use the working solution to stain the target slices for 10 minutes, and wash with running water for 30 seconds. Differentiate with hydrochloric acid ethanol solution for 15 seconds, return to blue with 0.1% ammonia water for 15 seconds, and wash with running water for 5 minutes. Stain with Ponceau red for 5 minutes. Wash with weak acid solution for 1 minute. The weak acid solution is 2mL acetic acid plus 1L water. Wash with molybdenum phosphate solution for 2 minutes. Wash with weak acid solution for 1 minute. Stain with aniline blue for 2 minutes. Wash with weak acid solution for 1 minute; dehydrate as usual; soak the slide holder in the transparent agent twice, each time for 10 minutes. Add neutral resin and cover with a coverslip. After drying overnight, scan the slices with a slice scanner for scanning and observation; the results are as follows Figure 6 shown.
[0089] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A decellularized matrix hydrogel modified bone scaffold, characterized in that: The decellularized matrix hydrogel modified bone scaffold is formed by in-situ cross-linking of the decellularized matrix hydrogel and the bone scaffold; the decellularized matrix hydrogel is prepared from tissues and organs in the embryonic period or the growth and development period; the bone scaffold includes at least one of autologous bone, xenogeneic bone and synthetic material.
2. The decellularized matrix hydrogel modified bone scaffold according to claim 1, characterized in that: The tissues and organs are of animal origin.
3. The decellularized matrix hydrogel modified bone scaffold according to claim 2, characterized in that: The tissues and organs include bone tissue and soft tissue.
4. The decellularized matrix hydrogel modified bone scaffold according to claim 1, characterized in that: The autologous bone and the allogeneic bone are both bone tissues of animal origin; the synthetic material includes at least one of bioglass, calcium phosphate, polylactic acid, and polyglycolic acid.
5. A method for preparing the acellular matrix hydrogel modified bone scaffold according to any one of claims 1 to 4, characterized in that: The steps include: (1) Taking bone tissue from animal sources, removing excess tissue, defatting, washing, drying, and calcining to obtain a bone scaffold; or taking synthetic materials and subjecting them to chemical treatment to obtain a bone scaffold; (2) taking tissues and organs from the embryonic stage or the growth and development stage, subjecting them to decellularization and matrix digestion treatment to obtain a decellularized matrix hydrogel stock solution; (3) The decellularized matrix hydrogel stock solution obtained in step (2) is mixed with the bone scaffold obtained in step (1), and the decellularized matrix hydrogel-modified bone scaffold is obtained by in situ cross-linking, freezing, and drying.
6. The method for preparing the decellularized matrix hydrogel-modified bone scaffold according to claim 5, characterized in that: In the step (2), the decellularization treatment method includes at least one of a physical method, a chemical method, and an enzymatic method.
7. The method for preparing the acellular matrix hydrogel-modified bone scaffold according to claim 5, characterized in that: In the step (2), the substrate is digested by enzymes.
8. The method for preparing the decellularized matrix hydrogel-modified bone scaffold according to claim 7, characterized in that: The enzyme comprises at least one of pepsin, trypsin, epithelial separation enzyme and collagenase.
9. Use of the acellular matrix hydrogel modified bone scaffold according to any one of claims 1 to 4 in the preparation of bone repair or bone regeneration materials.
10. The use according to claim 9, characterized in that The decellularized matrix hydrogel modified bone scaffold promotes bone repair or bone regeneration by inducing the microenvironment of the bone development period and the regression of stem cell development.
Citation Information
Cited By
Bionic cortical bone as well as preparation method and application thereof
CN122424422A
